Expression and function of androgen receptor in carcinoma of the prostate

Microscopy Research and Technique

Volumn 51, Issue 5, 2000, Pages 447-455

  Culig, Zoran ^a   Hobisch, Alfred ^a   Bartsch, Georg ^a   Klocker, Helmut ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Androgen receptor; Coactivators; Endocrine therapy; Ligand independent activation; Point mutations; Prostate cancer; Tumour progression

Indexed keywords

DISEASES; PROTEINS; UROLOGY;

ANDROGEN RECEPTORS; COACTIVATORS; ENDOCRINE THERAPY; GROWTH FACTOR; LIGAND-INDEPENDENT ACTIVATION; POINT MUTATIONS; PROSTATE CANCERS; PROTEIN KINASE A; RECEPTOR EXPRESSION; TUMOR PROGRESSIONS;

TRANSCRIPTION;

ANDROGEN; ANDROGEN RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENZYME ACTIVATOR; GROWTH FACTOR; MUTANT PROTEIN;

ANDROGEN THERAPY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RECEPTOR UPREGULATION; REVIEW; TUMOR GROWTH;

EID: 0034566055     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0029(20001201)51:5<447::AID-JEMT7>3.0.CO;2-M     Document Type: Review

References (121)

1. Aaltomaa S, Lipponen P, Eskelinen M, Ala-Opas M, Kosma VM. 1999. Prognostic value and expression of p21 (waf1/cip1) protein in prostate cancer. Prostate 39:8-15.
2. Aarnisalo P, Palvimo JJ, Janne OA. 1998. CREB binding protein in androgen receptor-mediated signaling. Proc Natl Acad Sci USA 95:2122-2127.
3. Alen P, Claessens F, Schoenmakers E, Swinnen JV, Verhoeven G, Rombauts W, Peeters B. 1999. Interaction of the putative androgen receptor-specific coactivator ARA70/ELE1 alpha with multiple steroid receptors and identification of an internally deleted ELE1beta isoform. Mol Endocrinol 13:117-128.
4. Aronica SM, Katzenellenbogen BS. 1993. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol 7:743-752.
5. Baretton GB, Klenk U, Diebold J, Schmeller N, Lohrs U. 1999. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer 80:546-555.
6. Berrevoets CA, Doesburg P, Steketee K, Trapman J, Brinkmann AO. 1998. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor 2). Mol Endocrinol 12:1172-1183.
7. Brady ME, Ozanne DM, Gaughan L, Waite I, Cook S, Neal DE. 1999. Tip60 is a nuclear hormone receptor coactivator. J Biol Chem 274:17599-17604.
8. Castagnaro M, Yandell D, Dockhorn-Dworniczak B, Wolfe H, Poremba C. 1993. Androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer. Verh Dtsch Ges Pathol 77: 119-123.
9. Chen S, Song CS, Lavrovsky Y, Bi B, Vellanoweth R, Chatterjee B, Roy AK. 1998. Catalytic cleavage of the androgen receptor messenger RNA and functional inhibition of androgen receptor activity by a hammerhead ribozyme. Mol Endocrinol 12:1558-1566.
10. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB. 1996. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56:3091-3102.
11. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. 1999. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 38:199-207.
12. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague JF, Scher HI. 1998. Distinct altered patterns of p27kip1 gene expression in benign prostate hyperplasia and prostate carcinoma. J Natl Cancer Inst 90:1284-1291.
13. Craft N, Shostak Y, Carey M, Sawyers CL. 1999. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280-285.
14. Cronauer MV, Nessler-Menardi C, Klocker H, Maly K, Hobisch A, Bartsch G, Culig Z. 2000. Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells. Br J Cancer 82:39-45.
15. Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H. 1993a. Mutant androgen receptor detected in an advanced stage of prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541-1550.
16. Culig Z, Klocker H, Eberle J, Kaspar F, Hobisch A, Cronauer MV, Bartsch G. 1993b. DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 22:11-22.
17. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. 1994. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478.
18. Culig Z, Hobisch A, Hittmair A, Cronauer MV, Radmayr C, Zhang J, Bartsch G, Klocker H. 1997. Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells. Prostate 32:106-114.
19. Culig Z, Hobisch A, Herold M, Hittmair A, Thurnher M, Eder IE, Cronauer MV, Rieser C, Ramoner R, Bartsch G, Klocker H, Konwalinka G. 1998. Interleukin-1β mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells. Br J Cancer 78:1004-1011.
20. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider M, Parczyk K, Klocker H. 1999. Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 81:242-251.
21. Darne C, Veyssiere G, Jean C. 1998. Phorbol ester causes ligand-independent activation of the androgen receptor. Eur J Biochem 256:541-549.
22. de Ruiter PE, Teuwen R, Trapman J, Dijkema R, Brinkmann AO. 1995. Synergism between androgens and protein kinase-C on androgen-regulated gene expression. Mol Cell Endocrinol 110:R1-R6.
23. Elo JP, Kvist L, Leinonen K, Isomaa V, Henttu P, Lukkarinen O, Vihko P. 1995. Mutated human androgen receptor gene detected in a prostate cancer patient is also activated by estradiol. J Clin Endocrinol Metab 80:3494-3500.
24. Fasciana C, van der Made AC, Faber PW, Trapman J. 1996. Androgen regulation of the rat keratinocyte growth factor (KGF/FGF7) promoter. Biochem Biophys Res Commun 220:858-863.
25. Fronsdal K, Engedal N, Hagsvold T, Saatcioglu F. 1988. CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. J Biol Chem 273:31853-31859.
26. Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC, Mizokami A, Chang C. 1999. Cloning and characterization of androgen receptor coactivator, ARA 55, in human prostate. J Biol Chem 274:8316-8321.
27. Gao J, Isaacs JT. 1998. Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells. Cancer Res 58:3299-3306.
28. Gao M, Ossowski L, Ferrari AC. 1999a. Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. J Cell Physiol 179:336-346.
29. Gao T, Brantley K, Bolu E, McPhaul MJ. 1999b. RFG (ARA70, ELE1) interacts with the human androgen receptor in a ligand-dependent fashion, but functions only weakly as a coactivator in cotransfection assays. Mol Endocrinol 13:1645-1656.
30. Goldman PS, Tran VK, Goodman RH. 1997. The multifunctional role of the co-activator CBP in transcriptional regulation. Recent Prog Horm Res 52:103-119.
31. Gong Y, Blok LJ, Perry JE, Lindzey JK, Tindall DJ. 1995. Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP. Endocrinology 136:2172-2178.
32. Gorelic LS, Lamm DL, Ramzy I, Radwin HM, Shain SA. 1987. Androgen receptors in biopsy specimens of prostate adenocarcinoma. Heterogeneity of distribution and relation to prognostic significance of receptor measurements for survival of advanced cancer patients. Cancer 60:211-219.
33. Grant ES, Batchelor KW, Habib F. 1996. Androgen independence of primary epithelial cultures of the prostate is associated with a down-regulation of androgen receptor gene expression. Prostate 29:339-349.
34. Gregory CW, Kim D, Ye P, D'Ercole AJ, Pretlow TG, Mohler JL, French FS. 1999. Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft. Endocrinology 140:2372-2381.
35. Guo Y, Kyprianou N. 1998. Overexpression of transforming growth factor-betal receptor type II restores transforming growth factor-betal sensitivity and signaling in human prostate cancer cells. Cell Growth Differ 9:185-193.
36. Guo Y, Sklar N, Borkowski A, Kyprianou N. 1997. Loss of the cyclin-dependent kinase inhibitor p27 (kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 3:2269-2274.
37. Gupta C, Chandorkar A, Nguyen AP. 1996. Activation of androgen receptor in epidermal growth factor modulation of fetal mouse sexual differentiation. Mol Cell Endocrinol 123:89-95.
38. Harris SE, Rong Z, Harris MA, Lubahn DB. 1990. Androgen receptor in human prostate carcinoma LNCaP/Adep cells contains a mutation which alters the specificity of the steroid-dependent transcriptional activation region. Program and Abstracts, 72nd Annual Meeting of the Endocrine Society, Atlanta, GA, p 93.
39. Henttu P, Vihko P. 1993. Growth factor regulation of gene expression in the human prostatic carcinoma cell line LNCaP. Cancer Res 53:1051-1058.
40. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. 1995. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 55:3068-3072.
41. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. 1996. Androgen receptor status of lymph node metastases from prostate cancer. Prostate 28:129-135.
42. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z. 1998. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58:4640-4645.
43. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. 1983. LNCaP model of human prostatic carcinoma. Cancer Res 43:1809-1818.
44. Hsiao PW, Chang C. 1999. Isolation and characterization of ARA160 as the first androgen receptor N-terminal-associated coactivator in human prostate cells. J Biol Chem 274:22373-22379.
45. Hsiao PW, Lin DL, Nakao R, Chang C. 1999. The linkage of Kennedy's neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator. J Biol Chem 274: 20229-20234.
46. Hsieh T, Wu JM. 1997. Induction of apoptosis and altered nuclear/ cytoplasmic distribution of the androgen receptor and prostate-specific antigen by 1alpha,25-dihydroxyvitamin D3 in androgen-responsive LNCaP cells. Biochem Biophys Res Commun 235:539-544.
47. Hsieh TC, Wu JM. 1999. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 249:109-115.
48. Hsieh TC, Xu W, Chiao JW. 1995. Growth regulation and cellular changes during differentiation of human prostatic cancer LNCaP cells as induced by T lymphocyte-conditioned medium. Exp Cell Res 218:137-143.
49. Huggins C, Hodges CV. 1941. Studies on prostatic cancer: The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297.
50. Ikonen T, Palvimo JJ, Janne OA. 1997. Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J Biol Chem 272:29821-29828.
51. Isaacs JT, Coffey DS. 1981. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 41:5070-5075.
52. Jarrard DF, Kinoshita H, Shi Y, Sandefar C, Hoff D, Meisner LF, Chang C, Herman JG, Isaacs WB, Nassif N. 1998. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res 58:5310-5314.
53. Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. 1997. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 3:2507-2511.
54. Kaighn ME, Shankar Narayan K, Ohnuki Y, Lechner JF, Jones LW. 1979. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17:16-23.
55. Kang HY, Yeh S, Fujimoto N, Chang C. 1999. Cloning and characterization of human prostate coactivator ARA 54, a novel protein that associates with the androgen receptor. J Biol Chem 274:8570-8576.
56. Kim IY, Kim JH, Zelner DJ, Ahn HJ, Sensibar JA, Lee C. 1996. Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP. Endocrinology 137:991-999.
57. Kokontis J, Takakura K, Hay N, Liao S. 1994. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 54:1566-1573.
58. Kokontis JM, Hay N, Liao S. 1998. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 12: 941-953.
59. Krongrad A, Wilson CM, Wilson JD, Allman DR, McPhaul MJ. 1991. Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells. Mol Cell Endocrinol 76:79-88.
60. Krusekopf S, Chaucherau A, Milgrom E, Henderson D, Cato ACB. 1991. Cooperation of progestational steroids with epidermal growth factor in activation of gene expression in mammary tumor cells. J Steroid Biochem Mol Biol 40:239-245.
61. Kyprianou N, Isaacs JT. 1988. Identification of a cellular receptor for transforming growth factor-beta in rat ventral prostate and its negative regulation by androgens. Endocrinology 123:2124-2131.
62. Kyprianou N, Isaacs JT. 1990. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol Mol Endocrinol 3:1515-1522.
63. Labrie F. 1991. Intracrinology. Mol Cell Endocrinol 78:C113.
64. Labrie F, Belanger A, Simard J, Labrie C, Dupont A. 1993. Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy. Cancer 71:1059-1067.
65. Lee C, Sutkowski DM, Zelner D, Kim I, Amsel I, Shaw N, Prins GS, Kozlowski JM. 1995. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 136:796-805.
66. Levine AC, Liu XH, Greenberg PD, Eliashvili M, Schiff JD, Aaronson SA, Holland JF, Kirschenbaum A. 1998. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology 139:4672-4678.
67. Lu S, Tsai SY, Tsai MJ. 1997. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res 57:4511-4516.
68. Lu S, Liu M, Epner DE, Tsai SY, Tsai MJ. 1999. Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 13:376-384.
69. Mitchell SH, Zhu W, Young C-Y. 1999. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 59:5892-5899.
70. Miyamoto H, Yeh S, Lardy H, Messing E, Chang C. 1998a. Delta 5-androstanediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci USA 95:11083-11088.
71. Miyamoto H, Yeh S, Wilding G, Chang C. 1998b. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 95:7379-7384.
72. Mizokami A, Yeh SY, Chang C. 1994. Identification of 3′5′-cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter. Mol Endocrinol 8:77-88.
73. Montgomery BT, Young CY, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF, Tindall DJ. 1992. Hormonal regulation of prostate-specific antigen (PSA) in the human adenocarcinoma cell line, LN-CaP. Prostate 21:63-73.
74. Nakhla AM, Romas NA, Rosner W. 1997. Estradiol activates the prostate androgen receptor and prostate-specific antigen secretion through the intermediacy of sex hormone-binding globulin. J Biol Chem 272:6838-6841.
75. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. 1997. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 3:2493-2500.
76. Nazareth LV, Stenoien DL, Bringman WE 3rd, James AJ, Wu C, Zhang Y, Edvards DP, Mancini M, Marcelli M, Lamb DJ, Weigel NL. 1999. A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1. Mol Endocrinol 13:2065-2075.
77. Nazareth LV, Weigel NL. 1996. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 271:19900-19907.
78. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER. 1992. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 89:6319-6323.
79. Nickerson T, Miyake H, Gleave ME, Pollak M. 1999. Castration-induced apoptosis of androgen-dependent Shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins. Cancer Res 59:3392-3395.
80. Nieh PT. 1995. Withdrawal phenomenon with the antiandrogen casodex. J Urol 153:1070-1072.
81. Nordeen SK, Bona BJ, Moyer ML. 1993. Latent agonistic activity of the steroid antagonist, RU 486, is unmasked in cells treated with activators of protein kinase A. Mol Endocrinol 7:731-742.
82. Okamoto M, Lee C, Oyasu R. 1997. Autocrine effect of androgen on proliferation of an androgen-responsive prostatic carcinoma cell line, LNCaP: role of interleukin-6. Endocrinology 138:5071-5074.
83. Olapade-Olaopa EO, MacKay EH, Taub NA, Sandhu DP, Terry TR, Habib FK. 1999. Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma. Clin Cancer Res 5:569-576.
84. Peterziel H, Culig Z, Stober J, Hobisch A, Radmayr C, Bartsch G, Klocker H, Cato ACB. 1995. Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding. Int J Cancer 63:544-550.
85. Prins GS, Sklarew RJ, Pertschuk LP. 1998. Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. J Urol 159:641-649.
86. Quarmby VE, Yarbrough WG, Lubahn DB, French FS, Wilson EM. 1990. Autologous down-regulation of androgen receptor messenger ribonucleic acid. Mol Endocrinol 4:22-28.
87. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, Brinkmann AO, Santerse AB, Schroder FH, van der Kwast TH. 1994. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144:735-746.
88. Sadi MV, Walsh PC, Barrack ER. 1991. Immunohistochemical study of androgen receptors in metastatic prostate cancer-comparison of receptor content and response to hormonal therapy. Cancer 67: 3057-3064.
89. Scher HI, Kelly WK. 1993. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566-1572.
90. Schuurmans ALG, Bolt J, Voorhost M, Blankenstein RA, Mulder E. 1988. Regulation of growth and epidermal growth factor receptor levels of LNCaP prostatic tumor cells by different steroids. Int J Cancer 42:917-922.
91. Small EJ, Carroll PR. 1994. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 43:408-410.
92. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. 1978. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21:274-281.
93. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki J. 1996. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 29:153-158.
94. Swinnen JV, van Veldhoven PP, Esquenet M, Heyns W, Verhoeven G. 1996. Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology 137:4468-4474.
95. Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven G. 1997. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res 57:1086-1090.
96. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock P, deVereWhite RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS. 1997. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 11:450-459.
97. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. 1999. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59: 2511-2515.
98. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. 1995. Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer. New Engl J Med 332:1393-1398.
99. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ. 1990. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 50:5382-5386.
100. Tilley WD, Lim-Tio SS, Horsfall DJ, Aspinall JO, Marshall VR, Skinner JM. 1994. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: Measurement by color video image analysis. Cancer Res 54:4096-4102.
101. Tilley WD, Buchanan G, Hickey TE, Bentel JM. 1996. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2:277-285.
102. Twillie DA, Eisenberger MA, Carducci MA, Hseih W-S, Kim WY, Simons JW. 1995. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45:542-549.
103. Van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CCJ, Mulder E, Boersma W, Trapman J. 1991. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48:189-193.
104. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, van Rooij HCJ, Trapman J, Brinkmann AO. 1990. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 17:534-540.
105. Veldscholte J, Berrevoets CA, Zegers ND, van der Kwast TH, Grootgoed JA, Mulder E. 1992. Hormone-induced dissociation of the androgen receptor-heat-shock protein complex: use of a new monoclonal antibody to distinguish transformed from nontransformed receptors. Biochemistry 31:7422-7430.
106. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP. 1995. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Gen 9:401-406.
107. Wilding G, Chen M, Gelman EP. 1989. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 14:103-115.
108. Wiren KM, Zhang X, Chang C, Keenan E, Orwoll ES. 1997. Transcriptional up-regulation of the human androgen receptor by androgen in bone cells. Endocrinology 138:2291-2300.
109. Wong CI, Kelce WR, Sar M, Wilson EM. 1995. Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J Biol Chem 270:19998-20003.
110. Yan G, Fukabori Y, Nikolaropoulos S, Wang F, McKeehan WL. 1992. Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. Mol Endocrinol 6:2123-2128.
111. Ye D, Mendelsohn J, Fan Z. 1999. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clin Cancer Res 5:2171-2177.
112. Yeap BB, Krueger RG, Leadman PJ. 1999. Differential posttranscriptional regulation of androgen receptor gene expression in prostate and breast cancer cells. Endocrinology 140:3282-3291.
113. Yeh S, Chang C. 1996. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 93:5517-5521.
114. Yeh S, Miyamoto H, Shima H, Chang C. 1998. From estrogen to androgen receptors: a new pathway for sex hormones in prostate. Proc Natl Acad Sci USA 95:5527-5532.
115. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. 1999. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96:5458-5463.
116. Young CYF, Montgomery BT, Andrews PE, Qiu S, Bilhartz DL, Tindall DJ. 1991. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 51:3748-3752.
117. Zegers ND, Claassen E, Neelen C, Mulder E, van Laar JH, Voorhorst MM, Berrevoets CA, Brinkmann AO, van der Kwast TH, Ruizeveld de Winter JA. 1991. Epitope prediction and confirmation for the human androgen receptor: generation of monoclonal antibodies for multi-assay performance following the synthetic peptide strategy. Bioch Biophys Acta 1073:23-32.
118. Zhao XY, Boyle B, Krishman AV, Navone NM, Peehl DM, Feldman D. 1999a. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol 162:2192-2199.
119. Zhao XY, Ly LH, Peehl DM, Feldman D. 1999b. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 140:1205-1212.
120. Zhau HY, Chang SM, Chen BQ, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LWK. 1996. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 93:15152-15157.
121. Zhu W, Smith A, Young CYF. 1999. A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of androgen receptor in LNCaP cells. Endocrinology 140:5451-5454.